9 Meters Biopharma Overview
Latest ROE for 9 Meters Biopharma: 790.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow790.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NMTR is 790.59%. That is above the Technology sector average of 47.96%. Investors often review this figure alongside 9 Meters Biopharma's historical trend and sector peers before judging valuation or financial health.
Against Technology companies, NMTR currently prints 790.59% for ROE, while the sector average sits near 47.96%. That is roughly 1548.5% above the sector mean. Large gaps often invite a closer look at 9 Meters Biopharma's growth, margins, and balance sheet.
Return on Equity shows how effectively 9 Meters Biopharma converts resources into returns. At 790.59%, NMTR may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NMTR's ROE (790.59%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack 9 Meters Biopharma's ROE against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.
